World Congress on
Controversies in Bone & Joint Diseases (C-Bone)

1st Announcement
& Call for Abstracts

Barcelona, Spain • January 20-23, 2011

A comprehensive Congress fully devoted to clinical debates and controversial issues in a wide spectrum of Bone and Joint Diseases

cbone@comtecmmed.com
www.comtecmmed.com/cbone
Welcome Letter

Dear Friends,

Over the years, the field of Bone & Joint Diseases has undergone enormous expansion in clinical and basic data, as well as that of field-related technology. With the problem of bone & joint diseases reaching epidemiological dimensions, treatment possibilities have digressed diversely. This development has created a need for debates on the numerous controversial issues, and to attain clinical conclusions.

The intention of the 1st World Congress on Controversies in Bone & Joint Diseases (C-Bone), which will take place January 20-23, 2011 in Barcelona, Spain, is to function as an exclusive forum for international experts to share and compare experiences, in order to outline appropriate treatment. A congress that focuses on clinical controversies is an entirely new concept. It is embarked upon primarily to facilitate effective debate on unresolved clinical and therapeutic dilemmas, resulting in agreement over all issues, and supported by evidence-based medicine and opinions of experts.

After each speaker, ample time will be provided for discussion, and participants will have the advantage of conversing and debating unresolved issues with world authorities in their fields. The Congress aims at reaching the ultimate state-of-the-art solutions, and providing clinicians with conclusive recommendations and reliable solutions, all based on current paramount significance.

The congress will conclude with a panel of distinguished experts presenting a consensus reached through the debates on Controversies in Bone & Joint Diseases.

We invite you to participate in the 1st World Congress on Controversies in Bone & Joint Diseases (C-Bone), which is intended as the first of many future congresses in this field.

We look forward to an exciting scientific event in the beautiful city of Barcelona.

Claus Christiansen
Congress Chairman
Scientific Committee - Partial List

Lars Arendt-Nieslen, Denmark
Roland Baron, USA
J.W. Bijlsma, Netherlands
Jean-Jacques Body, Belgium
Virginia Byers Kraus, USA
Juliet E. Compston, UK
Tobie de Villiers, South Africa
Richard Eastell, UK
Marco Gambacciani, Italy
Andrea Genazzani, Italy
Steven R. Goldring, USA
Peyman Hadji, Germany
Marc C. Hochberg, USA
Roman S. Lorenc, Poland
Thomas John Martin, Australia
Santiago Palacios, Spain
Serge Rozenberg, Belgium
Alan Tyndall, Switzerland

Local Organizing Committee - Partial List

Santiago Palacios, Spain
Antonio Cano, Valencia
Camil Castelo-Branco, Barcelona
Javier del Pino Montes, Salamanca
Manuel Diaz Curiel, Madrid
Adolfo Diez-Perez, Barcelona
Jesus Gonzalez Macias, Santander
Esteban Jodar Gimeno, Madrid
Manuel Sosa Henriquez, Las Palmas de Gran Canaria
Section: Osteoporosis

Session: Sex Steroids and Bone Health
Debate: Estrogen and estrogen-like molecules – do the benefits outweigh the risks?
Yes / No

Objectives:
- What did we learn from the WHI study?
- Are all selective estrogen receptor modulators (SERMs) the same?
- The timing hypothesis?
- What is the metabolic representation of a candidate for estrogen-like intervention – is there an optimal patient?

Session: Bone Stimulation
Debate: Do we need to stimulate bone formation to obtain an anabolic condition?

Objectives:
- The coupling of bone resorption and bone formation: Novel opportunities
- Is bone an endocrine organ? Other functions of bone cells
- The risk/benefit profile of drug development in OP – After FDA the evaluation of DMAB (anti RANK-L)
- Does bone quality play a role?
- The role of the gut and postprandial hormones in the regulation of bone turnover

Session: Menopausal Osteoporosis (OP)
Debate: What is the controversy regarding the possible intervention strategy for postmenopausal OP?

Objectives:
- Do biomarkers play a role in patient selections and selection of the optimal intervention?
- Risk factors for osteoporosis
- Cost/benefit scenarios and quality of life

Session: Parathyroid Hormone (PTH): Anabolic or Catabolic?
Debate: Do we understand the anabolic mode of action of PTH? A catabolic hormone!
Yes / No

Objectives:
- Differences in small molecule stimulators of endogenous PTH
- Failure of some Calcium mimetic programs

Session: Cathepsin K
Debate: Is cathepsin K intervention more than an anti-resorptive treatment?

Session: Antibody Interventions in Osteoporosis
Debate: Current and future antibody interventions in osteoporosis (DMAB and Anti-sclerositin)
Session: **Calcitonin I**
Debate: Does Oral Calcitonin Provide a Positive Calcium Balance?

---

Session: **Osteoporosis in Pre-menopausal Years?**
Debate: Should we actively look for diagnosis and treatment for Osteoporosis in women at the pre-menopausal years?

Objectives:
- Evaluation of secondary causes of bone loss in young women.
- Risk of low mineral density in women under 50- Discordances between Z-T scores in young adults.
- Bone turnover in pre-menopausal women receiving adjuvant chemotherapy.
- Medication used among pre-menopausal women with osteoporosis and low mineral density

---

Section: **Osteoarthritis**

Session: **Prevention and Treatment of Osteoarthritis (OA)**
Debate: Do we have effective mode of treatment or prevention for OA?
Yes / No

Objectives:
- The initiation and progression of OA
- Current approaches to OA treatment
- Identification of patient's disease by MRI
- Identification of patients’ disease by biochemical markers
- Identification of those with the greatest need of treatment by a combination of markers

---

Session: **Response to Treatment of Osteoarthritis (OA)**
Debate: Is bone remodeling the cause of or the consequence of OA? And do we need to target the bone in the development of drugs for OA?
Yes to both / No to both

Objectives:
- The role of subchondral bone turnover in OA
- Does cartilage quality play a role?
- The point of no return in cartilage turnover
- Can we design useful Phase II studies in OA?

---

Session: **Inflammation and Anti-Inflammatory in OA**
Debate: Synovial inflammation – a possible driver of later stage of disease progression? Do we need anti-inflammatory intervention strategies in OA?
Yes to both / No to both

Objectives:
- The role of synovial inflammation in joint damage and pain
- Inflammation – an initiator or a driving force of the disease?
- OA before and after synovial inflammation
- The role of inflammatory cells in OA
Session: New Indication for Existing Drug?
Debate: Can effective treatment for OP or RA also be effective in a selected patient population with OA?
Osteoporosis Drugs:
- SERMS
- Estrogen
- Bisphosphonates
- Cathepsin K
- Calcitonin
Rheumatoid Arthritis Drugs:
- Anti-TNF-alpha
- Anti-IL-1

---

Session: Controlling Pain in OA
Debate: Can we devise an optimal treatment for OA-related pain? Should pain be controlled centrally, peripherally, or both?
Objectives:
- Is there a difference between musculoskeletal and visceral pain?
- Central and local pain mediators
- Possible hormones that interfere with pain
- Pain-specific medication
- Novel possibilities and strategies

---

Session: Calcitonin II
Debate: Is oral calcitonin a possible dual action intervention strategy for osteoarthritis

---

Session: Glucosamine for OA
Debate: Does glucosamine have any role in OA?

---

Section: Rheumatoid Arthritis

Session: Monitoring Progression or Remission
Debate: Imaging, biochemical biomarkers, or both: Can they provide information on the progression or remission of OP, OA and RA?
Objectives:
- Can we better identify fast progressors in need of aggressive therapy?
- Biochemical markers in RA/OA/OP
- The molecular action mode of joint destruction
- The action mode of inflammation and immune systems in RA

---

Session: Choosing the Right Treatment for Patients with Rheumatoid Arthritis (RA)
Debate: Is there a difference between current available anti-inflammatory strategies in RA?
Objectives:
- CD20
- Different anti-TNF treatments
- Anti-IL-6
- Anti-IL-1
- P38 MAP kinase inhibitors
- Other intracellular opportunities and future treatment opportunities
Session: Glucocorticoids for Management of RA
Debate: Glucocorticoids without the side effects: Is this the future for treatment of RA?
Objectives:
- Can we find a strategy to reach the goal?
- Background on Glucocorticoids
- Bone and RA
- The cellular action mode of inflammatory, including macrophages and osteoclasts
- Subcellular cascades and key components leading to chronic inflammation
- Small molecule options in RA
- Bone an endocrine organ
- The role of the osteoclasts and bone degradation in RA

Session: Bone Metastasis
Debate: Are Bisphosphonates Anti-Cancer Drugs? Sclerostin as an Anabolic Agent for Bone Metastasis

Session: Late Breaking News and Hot Topics
Bone an endocrine organ
The role of the osteoclasts and bone degradation in RA

Call For Abstracts
An Exciting Opportunity
for young physicians, researchers and scientists!

The most outstanding research will be presented within the sessions of the invited lecturers

Please review the Scientific Program and while submitting your research abstract choose in which session you would like present

Scientific Program Link - www.comtecmed.com/cbone

Deadline for submitting abstracts for the main program - September 9, 2010
Deadline for Poster Presentations- October 10, 2010
General Information

Venue
Palau de Congressos de Catalunya
Av. Diagonal, 661-671, Barcelona 08028, Spain
Tel: +34 93 364 4400
Fax: +34 93 364 4401
Website: www.pcongresos.com

Language
The official language of the Congress is English.

Registration Fee

<table>
<thead>
<tr>
<th></th>
<th>Until October 20, 2010</th>
<th>From October 21, 2010</th>
<th>From January 16, 2011 and on site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Participants - Physicians and scientists</td>
<td>€540</td>
<td>€590</td>
<td>€650</td>
</tr>
<tr>
<td>Nurses, Students/ Trainees</td>
<td>€385</td>
<td>€430</td>
<td>€470</td>
</tr>
<tr>
<td>Residents*</td>
<td>€320</td>
<td>€380</td>
<td>€420</td>
</tr>
<tr>
<td>Accompanying Persons</td>
<td></td>
<td></td>
<td>€150</td>
</tr>
</tbody>
</table>

Registration includes: Participation in scientific sessions, Congress Delegate bag, all printed material of the Congress, invitation to the Welcome Reception, coffee breaks, lunch on Friday and Saturday.

Accommodation
ComtecMed is the official travel agent for the World Congress on Controversies in Bone & Joint Disease (C-Bone), and will be offering special reduced rates for accommodation.

Submission of Abstracts
Participants, who wish to give a presentation at the Congress, are requested to submit an abstract for review by the Scientific Committee. Abstract Submission Deadline for submitting abstracts for the main program is September 9, 2010. Abstract Submission Deadline for Poster Presentations is October 10, 2010.

Congress Organizers
Please do not hesitate to contact the Organizers if you require any additional information or assistance. Please address all correspondence to: cbone@comtecmed.com, Tel: +972-3-5666166

Liability and Insurance
The organizer carries no liability whatsoever for injuries or damages involving persons and/or property during the Congress. Participants are advised to issue their own personal travel and health insurance for their trip.